CX 157
Alternative Names: CX157; KP 157; TriRima; TyrimaLatest Information Update: 27 Jun 2013
Price :
$50 *
At a glance
- Originator Krenitsky Pharmaceuticals
- Developer CeNeRx BioPharma
- Class Antidepressants; Anxiolytics; Small molecules
- Mechanism of Action Monoamine oxidase A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Anxiety disorders; Major depressive disorder
Highest Development Phases
- Discontinued Anxiety disorders; Major depressive disorder
Most Recent Events
- 27 Jun 2013 CX 157 is available for licensing globally as of 27 Jun 2013.
- 27 Jun 2013 Discontinued - Phase-I for Anxiety disorders in USA (PO)
- 27 Jun 2013 Discontinued - Phase-II for Major depressive disorder (treatment-resistant) in USA (PO)